NEW
YORK, Feb. 10, 2025 /PRNewswire/ -- Baird
Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or
the "Company"), a leader in microwave ablation (MWA) technology,
remains committed to advancing physician education and recently
supported Dr. Hosai Todd-Hesham's
participation in a specialized MWA training program at the Columbia
Thyroid Center in New York
City.
Led by Dr. Jennifer Kuo, Director
of the Interventional Endocrinology Program and Program Director of
the Endocrine Surgery Fellowship at Columbia
University's Department of Surgery, the two-day course
provided in-depth instruction on MWA techniques, procedural safety,
and clinical applications. The program attracted physicians from
the United States and Mexico, including Dr. Hosai Todd-Hesham, an Otolaryngology specialist
from Maryland ENT Associates, and Dr. Camilo González Velázquez,
Associate Professor and Endocrinologist at Hospital Universitario
Dr. José E. González.
During the hands-on training session, Dr. Hesham, under the
expert guidance of Dr. Kuo, performed simulated procedures using a
thyroid model. She focused on mastering device operation, enhancing
ablation precision, and making real-time procedural adjustments.
This structured training allowed her to systematically refine her
expertise in thyroid MWA, further strengthening her skills in
minimally invasive techniques.
The live case observation session proved highly beneficial for
the participating physicians. Through three procedures, they gained
deeper insights into MWA's preoperative planning, intraoperative
techniques, and postoperative patient management. The practical
nature of the training received high praise from attendees. Dr.
Hesham described the experience as a solid foundation that enhanced
her confidence and interest in microwave ablation technology. Dr.
Velázquez emphasized the irreplaceable value of hands-on clinical
experience, noting that many procedural nuances extend beyond
textbook knowledge. One notable case involved the ablation of a 5cm
thyroid nodule, where the patient experienced significant symptom
relief and a smooth recovery, further demonstrating MWA's precision
and minimally invasive advantages in treating larger nodules.
As a pioneer in microwave ablation, Baird Medical is dedicated
to accelerating the adoption of innovative, minimally invasive
treatments through specialized training and collaboration. By
expanding its global MWA education network, the Company aims to
provide physicians with standardized and comprehensive training to
enhance procedural expertise. Through these efforts, Baird Medical
empowers more doctors to deliver safer, more effective treatments,
improving outcomes and quality of life for patients worldwide.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave
ablation (MWA) technology, offering advanced treatment solutions
for conditions such as thyroid nodules, breast disease, uterine
fibroids, and liver cancer. A publicly traded company on NASDAQ,
Baird Medical is dedicated to enhancing patient care through
precision, efficiency, and safety in its innovative medical
devices. For more information, please visit
https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts and generally relate to future events or
Baird Medical's future financial or operational performance. In
some cases, you can identify forward-looking statements by
terminology such as "may," "might," "will," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue," or the negative of these terms or other
similar expressions.
These forward-looking statements are subject to risks,
uncertainties, and assumptions that could cause actual results or
outcomes to differ materially from those expressed or implied.
These statements are based on estimates and assumptions that, while
considered reasonable by Baird Medical and its management, are
inherently uncertain. Risks and uncertainties may emerge over time,
and it is not possible to anticipate all potential factors that
could affect Baird Medical's business and financial
performance.
Factors that could cause actual results to differ materially
include, but are not limited to: (1) the risk that Baird Medical
may not achieve its expansion goals in the United States, China, or other markets; (2) changes in
economic, regulatory, or market conditions that impact Baird
Medical's operations; (3) the ability to realize anticipated
benefits from ongoing business initiatives or strategic
transactions; (4) regulatory developments and compliance with
applicable laws; (5) risks related to the development,
commercialization, and market acceptance of Baird Medical's
products; and (6) other risks and uncertainties detailed in Baird
Medical's filings with the SEC.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. Baird Medical undertakes no obligation to update or
revise forward-looking statements, whether as a result of new
information, future events, or otherwise, except as required by
law. All forward-looking statements in this press release are
qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-advances-mwa-training-with-expert-led-course-at-columbia-thyroid-center-302371852.html
SOURCE BDMD
